NADP Executive Board member Cornelis Boersma appointed professor of “Sustainable Care and Innovation”
Cornelis Boersma, member of the NADP Executive Board, has been appointed professor of “Sustainable Care and Innovation” at the Open University in the Netherlands. The chair at the Nijmegen School of Management was established by VEROZ, the knowledge center for promoting innovation and entrepreneurship in healthcare.
The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial Resistance Benchmark provides the only independent measure of how pharmaceutical companies are responding. The methodology for 2021 prioritises the tracking of progress and a deeper exploration of the headwinds faced by biotechs driving novel R&D.
A record number of countries are now monitoring and reporting on antibiotic resistance – marking a major step forward in the global fight against drug resistance. But the data they provide reveals that a worrying number of bacterial infections are increasingly resistant to the medicines at hand to treat them.
Companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline that fulfil the below inclusion criteria. Data submitted should be non-confidential and will be made available publicly on the WHO Global Health R&D Observatory.
Identifying potential antibiotic leads is painfully slow, but these researchers identified 5 in only 6 years
ENABLE surpassed their goal of identifying 3 leads for new antibiotics. With several more compounds in the pipeline, the project has been extended.
On 28 and 29 January, the Access to Medicine Foundation will host an investor webinar about the newly published 2020 AMR Benchmark. It will provide investors with an introduction about the materiality of AMR for the pharmaceutical industry and present the results from the most recent independent comparison of how 30 different pharmaceutical companies are responding to rising rates of drug-resistant infections.